• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

Federated Hermes Impact Opportunities Equity Fund Class F2 GBP Acc

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund Provider Hermes Fund Managers Ireland Ltd
Fund Summary The investment objective of the Fund is to achieve long term capital appreciation by investing in companies which will benefit from meeting the worlds environmental and social challenges.
SEDOL code BD3FNV4
ISIN IE00BD3FNV41
Fund code HEIOA
Managers Martin Todd, Mark Sherlock
Manager Tenure 1 year
Morningstar Category Global Flex-Cap Equity
IMA Sector Global
Fund Size £217 million
Fund Type OEIC
Management Style Active
Ongoing Charge Figure (OCF) 0.95%
Cavendish ongoing charge 0.05%
FundsNetwork Service Fee 0.20%
Minimum Initial Investment £25
Minimum Top Up £25
Minimum Monthly Investment £25
Sell Price £1.3403
Buy Price £1.3403
Price Change +1.2388%
Price Date 3rd July 2020
Yield Currently unavailable
Dividend Frequency Semi-Annually
ISA Eligible Yes
SIPP Eligible Yes
Inception Date 3rd April 2018
Fund Status OPEN

3-year Mean Monthly Return: Currently unavailable

Annual Returns 2019 2018
Fund Performance +9.97% +15.50%
Benchmark Performance
(Global Flex-Cap Equity)
+0.13% +1.07%
Time Period Cumulative Benchmark Performance
(Global Flex-Cap Equity)
Fund Compared to Benchmark
1 day 1.24% -1.21% +2.45%
1 week 1.63% +2.59% -0.96%
1 month 0.71% +25.75% -25.03%
3 months 24.77% -2.42% +27.20%
6 months 6.52% -0.38% +6.90%
1 year 8.94% +0.89% +8.05%
3 years Currently unavailable Currently unavailable Currently unavailable
5 years Currently unavailable Currently unavailable Currently unavailable
10 years Currently unavailable Currently unavailable Currently unavailable
YTD 6.45% +0.96% +5.49%
Since inception 12.26% Currently unavailable Currently unavailable

Top 10 shares for this fund

Share Name Country Value
Qiagen NV USA 5.10%
Orsted A/S DNK 4.64%
Novo Nordisk A/S B DNK 4.48%
Agilent Technologies Inc USA 4.22%
Lonza Group Ltd CHE 4.08%
CSL Ltd AUS 4.07%
Illumina Inc USA 4.07%
Abcam PLC GBR 4.05%
Ansys Inc USA 3.98%
Xylem Inc USA 3.97%

Currently unavailable